{"id":87111,"title":"Open Orphan PLC (ORPH.L) Notice of Interim Results","publisher":"Share Talk","author":"sharetalk","published":"2021-09-09T07:23:10+00:00","modified":"2021-09-09T07:23:10+00:00","canonical_url":"https://www.share-talk.com/open-orphan-plc-orph-l-notice-of-interim-results/","markdown_url":"https://www.share-talk.com/open-orphan-plc-orph-l-notice-of-interim-results.md","json_url":"https://www.share-talk.com/open-orphan-plc-orph-l-notice-of-interim-results.json","category":"Healthcare","categories":["Healthcare","Pharmaceutical"],"tags":["Andrew Catchpole","antiviral","breast cancer","Caroline Clarke","Cathal Friel","CHIMagents","clinical respiratory drug","Codagenix","COVID-19","Dengue Fever","Dr Andrew Catchpole","Dr Chris Chiu","Gregory Stoloff","HRV","hVIVO","ImmunoTech Inc","Imperial College London","Imutex Ltd","Influenza","IPO","laboratory","Malaria","Open Orphan","ORPH","Oxford BioTherapeutics","pharmaceutical","Poolbeg Pharma plc","quarantine clinic","Rahim Fandi","Royal Free London group","Sabine Specht","The Lancet","Thomas K. Equels","Vaccine","Venn Life Sciences","virology","West Nile Virus","Zika"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1","format":"news","language":"en-GB","content":"**Open Orphan plc (AIM: ORPH),** a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that its interim results for the six-month period ended 30 June 2021 will be released on Monday, 20 September 2021.\n\n**Analyst Briefing**\n\nA briefing open to analysts will take place remotely via video conference call on Monday 20 September at 9.30am (BST). If you would like the details of this call, please contact Walbrook PR on openorphan@walbrookpr.com.\n\n**Investor Presentation**\n\nCathal Friel, Executive Chairman, and Leo Toole, Chief Financial Officer, will provide a live presentation relating to the interim results via the Investor Meet Company platform on Monday, 20 September 2021 at 6.00pm (BST).\n\nThe presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.\n\nInvestors can sign up to Investor Meet Company for free and add to meet Open Orphan plc via:\n\n[https://www.investormeetcompany.com/open-orphan-plc/register-investor](https://www.investormeetcompany.com/open-orphan-plc/register-investor)\n\nInvestors who already follow Open Orphan plc on the Investor Meet Company platform will automatically be invited.\n\n**For further information please contact:**\n\n**Open Orphan plc**\n\n**+353 (0) 1 644 0007**\n\n**Notes to Editors**\n\nOpen Orphan plc (London and Euronext: ORPH) is a rapidly growing pharmaceutical service/contract research company that is a world leader in testing vaccines and antivirals using human challenge clinical trials. The company provides services to Big Pharma, biotech and government/public health organisations.\n\nOpen Orphan runs challenge studies in London from both its 19-bedroom Whitechapel quarantine clinic, opened in February 2021, and its 24-bedroom QMB clinic with its highly specialised on-site virology and immunology laboratory. Open Orphan has a leading portfolio of human challenge study models for infectious and respiratory diseases and is developing a number of other models including the world’s first COVID-19 human challenge study model as part of the Human Challenge Programme .\n\nBuilding upon its many years of challenge studies and virology research, the Company is developing an in-depth database of infectious disease progression data. Based on the Company’s Disease in Motion® platform, this unique dataset includes clinical, immunological, virological and digital (wearable) biomarkers. The Disease in Motion platform has many potential applications across a wide variety of end users including big technology, wearables, pharma and biotech companies. Following COVID-19 there is now a renewed interest and investment in infectious diseases.\n\nOpen Orphan’s Paris office has been providing biometry, data management and statistics to its many European pharmaceutical clients for over 20 years. For over 15 years, the Company’s Netherlands office has been providing drug development consultancy and services, including CMC (chemistry, manufacturing and controls), PK and medical writing, to a broad range of European clients. Both offices are now also fully integrated with the London office and working on challenge study contracts as well as supporting third party trial contracts ."}